Cline: trading with BTA starts tomorrow

Cline Scientific AB (publ) ("Cline" or the "Company") announces that trading with BTA starts tomorrow 1st  August 2023.

 Trading in paid subscribed shares (BTA) takes place on the Nasdaq First North Growth Market until the conversion of BTA into shares, which takes place after the rights issue has been registered with the Swedish Companies Registration Office. Registration with the Swedish Companies Registration Office is expected to take place at the end of August 2023.

For more information, please contact:
Hanne Evenbratt, CEO
Email: hanne.evenbratt@clinescientific.com
Phone: +46 704 88 79 23 

Patrik Sundh, board member
Email: patrik.sundh@clinescientific.com
Phone: +46 0703585088

Cline Scientific AB (publ)                                                 Phone: 031-387 55 55
Argongatan 2 C                                                                   Email: info@clinescientific.com
431 53  MÖLNDAL                                                              Website: www.clinescientific.com

About Cline Scientific
Cline Scientific develops advanced cancer diagnostics and regenerative medicine treatments. Cline’s unique patented surface nanotechnology provides solutions to critical challenges for cell-based products and process in Life Science. Cline is driving two projects through to a clinical stage, StemCART - a stem cell therapy for joint repair, and CellRACE- a cancer diagnostic to predict metastasis.